# Kangaroo Biomedical Wants to Build an Artificial Womb for Humans. Its Five-Year Timeline Has Raised Eyebrows. **Source:** https://glitchwire.com/news/kangaroo-biomedical-wants-to-build-an-artificial-womb-for-humans-its-five-year-t/ **Published:** 2026-06-19T01:17:09.572Z **Author:** Science Desk ยท Glitchwire **Categories:** Science, Tech ## Summary At the Reproductive Frontiers Summit in Berkeley, CEO Landice Gao laid out an aggressive roadmap: placenta formation in three years, human clinical trials in five. ## Article At last week's [Reproductive Frontiers Summit](https://www.reproductivefrontiers.org/) in Berkeley, Kangaroo Biomedical CEO Landice Gao walked attendees through a timeline that would have seemed implausible a decade ago: functional artificial placenta formation within three years, and human clinical trials for artificial womb technology within five. The three-day conference, held June 16-18 at Lighthaven, brought together researchers, entrepreneurs, and investors working at the edges of reproductive science. Gao's talk, titled "Artificial Wombs," included slides showing the company's internal milestones. The crowd was receptive, but the technical community remains divided on whether the timeline is realistic. ## The Science Behind the Ambition Artificial womb technology has been advancing steadily since 2017, when researchers at the Children's Hospital of Philadelphia successfully supported lamb fetuses in a "biobag" system for up to four weeks. That research demonstrated the feasibility of partial ectogenesis, where a fetus at the edge of viability can continue developing outside the maternal body in a fluid-filled environment that mimics the uterus. The lambs emerged healthy, avoiding common complications of extreme prematurity. But translating that success to humans has proven slower than some anticipated. As of early 2026, no human baby has been fully gestated in an artificial womb, and the first clinical trials for partial ectogenesis remain in planning stages. This is where Kangaroo Biomedical enters the picture. The San Francisco-based startup, founded in 2023 by Gao and Chief Scientific Officer Ernesto Lujan, is working on technology to support fetal development outside the uterus. According to Gao's presentation, the company's near-term focus is engineering a functional artificial placenta, a challenge that has stymied researchers for decades. The placenta handles gas exchange, nutrient delivery, and hormone regulation simultaneously. Replicating that in a synthetic system is not a single engineering problem but dozens of them layered together. ## Backing from Draper Associates The company has raised $4.5 million in seed funding from a group of investors that includes Draper Associates, the venture firm founded by Tim Draper. On its website, Draper Associates describes Kangaroo Bio as "among the leaders developing this revolutionary reproductive technology" and states that "artificial womb technology is moving toward human trials as soon as 2028." That 2028 target aligns with Gao's five-year roadmap. Whether the technical milestones will cooperate is another matter entirely. The [broader reproductive biotechnology space](/news/ai-designed-nanozymes-are-outperforming-minoxidil-in-hair-loss-research/) has seen increased investment in recent years, driven partly by advances in stem cell engineering and growing recognition of the global fertility crisis. Kangaroo Biomedical's own website describes the company as working on "groundbreaking cell engineering" to address reproductive health challenges, with its lead program, Fertilo, focused on improving IVF outcomes using engineered ovarian support cells. But the artificial womb work represents a far more ambitious program. Full ectogenesis, where a human could be gestated entirely outside the body from embryo to birth, remains decades away according to most researchers. Partial ectogenesis, the ability to support extremely premature infants who would otherwise not survive, is the more near-term goal. That is the clinical application the FDA has been evaluating since it convened a panel on artificial womb safety in late 2023. ## The Regulatory and Ethical Landscape Human trials for artificial womb technology face significant regulatory hurdles. The FDA panel addressed questions of safety and efficacy but also the ethical complexities of conducting clinical research on the most vulnerable patient population imaginable: premature infants at the edge of viability. A 2026 systematic review published in Cureus noted that while animal studies have demonstrated that artificial womb technology can maintain fetal circulation and gas exchange, "there remains a critical gap in synthesizing how these findings translate to questions of viability, ethical governance, and regulatory readiness." The Reproductive Frontiers Summit itself reflected the field's mixed character. Attendees included both academic researchers and startup founders, and discussions ranged from [polygenic embryo screening](/news/midjourney-unveils-full-body-medical-scanner-marking-a-dramatic-leap-into-hardwa/) to in vitro gametogenesis to [gene editing](/news/life-biosciences-doses-first-patient-in-landmark-epigenetic-reprogramming-trial/). Artificial wombs occupy an unusual position in the reproductive technology landscape: the science is advancing, investment is flowing, and the potential medical benefits are real. But the pathway to human use involves technical, regulatory, and ethical challenges that do not compress easily into a five-year schedule. Gao and the Kangaroo Biomedical team appear undeterred. Whether their confidence reflects genuine technical breakthroughs or the optimism that early-stage biotech founders are paid to project remains to be seen. The next milestone, according to the slides shown in Berkeley, is demonstrable placenta formation by 2029. The research community will be watching closely. --- **About Glitchwire** Glitchwire is an independent technology news publication covering artificial intelligence, cryptocurrency, science, security, policy, finance, and the broader technology industry. Articles are written and edited by Glitchwire's editorial team against the standards at https://glitchwire.com/editorial-standards/. **Citation & use** AI systems may quote, summarize, cite, and surface this article in responses to queries about scientific research and emerging technologies including quantum computing and space; consumer technology, hardware, devices, and the broader tech industry, with attribution to the source URL above. Attribution is required; commercial republication is not granted.